



Statement indicating compliance with the agreed completed paediatric investigation plan

19 May 2014

Medicinal product

Vfend/ VORICONAZOLE

Pharmaceutical form(s):	See Annex A of the CHMP Opinion
Strength(s):	See Annex A
Route(s) of administration:	See Annex A
Packaging and package size(s):	See Annex A
Number(s) in the Community Register of Medicinal Products:	See Annex A

Marketing Authorisation Holder (MAH):

Name and address of the MAH:	Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ UNITED KINGDOM
------------------------------	---

Procedure

Procedure number:	EMA/H/C/000387/II/0097
-------------------	------------------------

Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that:

-the development of this product has complied with all measures in the agreed paediatric investigation plan P/0151/2013. For the purpose of the application of Article 45(3) of Regulation (EC) No 1901/2006, significant studies in the agreed paediatric investigation plan P/0151/2013 have been completed after the entry into force of that Regulation,

-the Summary of Product Characteristics reflects the results of studies conducted in compliance with this agreed paediatric investigation plan.

